Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study

Ashida, Ryo; Nakamura, Kiyonao; Aizawa, Rihito; Iramina, Hiraku; Takayama, Kenji; Nakamura, Mitsuhiro; Mizowaki, Takashi

doi:10.1007/s11604-021-01186-6

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The longest reported follow-up time was 124 months [49]. In the planning studies, as shown in Table 2, the majority of studies utilized mpMRI for GTV delineation [10,18,45,[57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75]. Five studies utilized PET-CT [12,[76][77][78][79][80], and four studies used "other methods" such as histopathology data or hypothetical IPLs [81][82][83][84].…”

Section: Statistics Of Reviewed Studiesmentioning

confidence: 99%

Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials

Zhao,

Haworth,

Rowshanfarzad

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Focal boost radiotherapy was developed to deliver elevated doses to functional sub-volumes within a target. Such a technique was hypothesized to improve treatment outcomes without increasing toxicity in prostate cancer treatment. Purpose: To summarize and evaluate the efficacy and variability of focal boost radiotherapy by reviewing focal boost planning studies and clinical trials that have been published in the last ten years. Methods: Published reports of focal boost radiotherapy, that specifically incorporate dose escalation to intra-prostatic lesions (IPLs), were reviewed and summarized. Correlations between acute/late ≥G2 genitourinary (GU) or gastrointestinal (GI) toxicity and clinical factors were determined by a meta-analysis. Results: By reviewing and summarizing 34 planning studies and 35 trials, a significant dose escalation to the GTV and thus higher tumor control of focal boost radiotherapy were reported consistently by all reviewed studies. Reviewed trials reported a not significant difference in toxicity between focal boost and conventional radiotherapy. Acute ≥G2 GU and late ≥G2 GI toxicities were reported the most and least prevalent, respectively, and a negative correlation was found between the rate of toxicity and proportion of low-risk or intermediate-risk patients in the cohort. Conclusion: Focal boost prostate cancer radiotherapy has the potential to be a new standard of care.

show abstract

Section: Statistics Of Reviewed Studiesmentioning

confidence: 99%

Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials

Zhao,

Haworth,

Rowshanfarzad

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study

Abstract: Ashida, Ryo ...[et al]. Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study.

Cited by 1 publication

References 36 publications

Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials

Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials

Contact Info

Product

Resources

About